Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Hoffmann la Roche Inc
Hoffmann la Roche Inc_20131212

Hoffmann la Roche Inc patents


Recent patent applications related to Hoffmann la Roche Inc. Hoffmann la Roche Inc is listed as an Agent/Assignee. Note: Hoffmann la Roche Inc may have other listings under different names/spellings. We're not affiliated with Hoffmann la Roche Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "H" | Hoffmann la Roche Inc-related inventors


Pharmaceutical formulation comprising sembragiline

The invention relates to pharmaceutical formulation in form of a film-coating tablet comprising sembragiline or a salt thereof.... Hoffmann la Roche Inc

Substituted pyrazino[2,2-a]isoquinoline derivatives

The present invention relates to compounds of formula of formula I wherein R, R1, R2 and L are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.... Hoffmann la Roche Inc

Monovalent antigen binding proteins

The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.... Hoffmann la Roche Inc

Process for making lysine-glutamic acid dipeptide derivatives

and to a process for making same and to the use of the products in the solid phase peptide synthesis. The compounds of formula I are versatile peptide intermediates for the solid phase peptide synthesis (SPPS) of peptide drugs which comprise a Glu-fatty alkyl side chain building block attached to... Hoffmann la Roche Inc

Bicyclic quinazolinone derivatives

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R12, R13, R14, A1, A2, A3, n and m are as described herein.... Hoffmann la Roche Inc

Screening method

... Hoffmann la Roche Inc

Method and electrostatically discharging a primary packaging container made of plastics

A method and an apparatus (100) for electrostatically discharging a primary packaging container (102) made of plastics are disclosed. The method comprises moving a primary packaging container (102) to be electrostatically discharged so as to pass at least one electrode (104, 106, 108), applying an alternating voltage to the electrode... Hoffmann la Roche Inc

Assay and determining cdc eliciting antibodies

Herein is reported a method for determining complement dependent cytotoxicity of a composition comprising i) a first binding site that specifically binds to a first epitope on a first antigen, which is conjugated to a first Fc-region polypeptide of human origin, and ii) a second binding site that specifically binds... Hoffmann la Roche Inc

Multistep final filtration

Herein is reported a method for the final filtration of concentrated polypeptide solutions comprising the combination of two immediately consecutive filtration steps with a first filter of 3.0 μm and 0.8 μm pore size and a second filter of 0.45 μm and 0.22 μm pore size.... Hoffmann la Roche Inc

Feed mixing device and its use

Herein is reported a feed mixing device for adding feed solutions with a non-physiologically pH value to a cell cultivation vessel comprising a chamber for mixing the feed solutions prior to their addition to the cell cultivation vessel as well as its use. With the feed mixing device as reported... Hoffmann la Roche Inc

Quality control of automated whole-slide analyses

The subject disclosure presents systems and methods for automatically selecting meaningful regions on a whole-slide image and performing quality control on the resulting collection of FOVs. Density maps may be generated quantifying the local density of detection results. The heat maps as well as combinations of maps (such as a... Hoffmann la Roche Inc

Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor

The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV capsid assembly inhibitor for use in the treatment of chronic hepatitis B patient.... Hoffmann la Roche Inc

Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies

The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.... Hoffmann la Roche Inc

Ethynyl derivatives

The present invention relates to compounds that may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.... Hoffmann la Roche Inc

Cell penetrating peptides

Provided herein are cell penetrating peptides optionally including a cargo moiety linked thereto.... Hoffmann la Roche Inc

Bispecific anti-vegf/anti-ang-2 antibodies

The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.... Hoffmann la Roche Inc

Multispecific antibodies

The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.... Hoffmann la Roche Inc

Activity assay for bond forming enzymes

and thereby detecting the sortase in the sample.... Hoffmann la Roche Inc

Subcutaneously administered anti-il-6 receptor antibody

The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of... Hoffmann la Roche Inc

Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon

The present invention provides a stable, isotonic, aqueous solution formulation comprising: (i) 0.1-0.5 mg/mL alpha-type interferon, preferably pegylated alpha-type interferon; (ii) 20 mM Acetate buffer system to maintain a pH of 6.0±0.5; (iii) 5-20 mM L-methionine; (iv) 120-150 mM sodium chloride; (v) 0.01-0.07 percent by weight of a surfactant effective... Hoffmann la Roche Inc

New trifluoromethylpropanamide derivatives

wherein R1, R2, R3, R4, R5, R6 and R7 are as described herein, compositions including the compounds and methods of using the compounds.... Hoffmann la Roche Inc

Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists

The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.... Hoffmann la Roche Inc

Multispecific antibodies

The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.... Hoffmann la Roche Inc

Poly oligomer compound with biocleavable conjugates

The invention relates to the field of oligonucleotide therapeutics, and in particular to poly oligo oligonucleotides conjugates where two or more antisense oligonucleotides are covalently linked by physiologically labile linkers, and to a biocleavable functional group such as a conjugate group.... Hoffmann la Roche Inc

Method for providing in a primary packaging container a dried solid product containing an active pharmaceutical ingredient

A method for providing a dried solid product containing an active pharmaceutical ingredient is disclosed and includes providing a primary packaging container, providing a drying cartridge different from the primary packaging container, the drying cartridge made of a material adapted to hold a liquid product to be dried, wherein the... Hoffmann la Roche Inc

Novel 2-oxo-6, 7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection

wherein R1, R2, R3, R4, R5 and Ar are as described herein, compositions including the compounds and methods of using the compounds.... Hoffmann la Roche Inc

Method for producing monomeric and multimeric molecules and uses thereof

Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (Bn-CSo-Is-CSp-FC-CSq-ItCSr-Bm)u, wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the... Hoffmann la Roche Inc

Fc-region variants with modified fcrn-binding and methods of use

Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein a) the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class... Hoffmann la Roche Inc

Fc-region variants with modified fcrn- and protein a-binding properties

Herein is reported a heterodimeric polypeptide comprising a first polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, and a second polypeptide comprising in N-terminal to C-terminal direction at... Hoffmann la Roche Inc

Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody

Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region... Hoffmann la Roche Inc

Syringe and preparing syringe

A syringe (18) has a longitudinal body (28) with an interior (228) in which a pharmaceutical substance is arranged, a needle connected to one longitudinal end of the body (228) and a rigid needle shield (38) encasing the needle. The rigid needle shield (38) is essentially water vapour tight. The... Hoffmann la Roche Inc

Bace1 inhibitors

The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.... Hoffmann la Roche Inc

Anti-alpha-synuclein antibodies and methods of use

The invention provides anti-human alpha-synuclein antibodies and methods of using the same.... Hoffmann la Roche Inc

11/16/17 / #20170327797

Recombinant hbv cccdna, the method to generate thereof and the use thereof

The present invention relates to a recombinant HBV cccDNA comprising HBV genome or the fragment or variant thereof and a site-hybrid insert, a method to generate said recombinant HBV cccDNA, a method for establishment of an in vitro or in vivo cccDNA based model for persistently hepatitis B virus replication... Hoffmann la Roche Inc

11/16/17 / #20170328914

Biomarkers of fast progression of chronic kidney disease

The present invention relates to methods for the prediction of the progression of chronic kidney disease in a patient. More particularly, the invention relates to the early prediction of the fast progression of chronic kidney disease using specific biomarker signatures in urine sample of patients.... Hoffmann la Roche Inc

11/16/17 / #20170327524

Galnac phosphoramidites, nucleic acid conjugates thereof and their use

This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine.... Hoffmann la Roche Inc

11/09/17 / #20170320912

Peptides

The present invention relates to dual-site BACE1 inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.... Hoffmann la Roche Inc

11/09/17 / #20170320953

Antibodies against human csf-1r and uses thereof

The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.... Hoffmann la Roche Inc

11/09/17 / #20170322225

Biomarkers and methods of prediction

Subject of the present invention are biomarkers and methods for the identification of risk for subsequent cardiovascular event (e.g. coronary heart disease death, non-fatal myocardial infarction, ischemic stroke, hospitalizations for unstable angina pectotis, cardiac arrest) in patients that have experienced an acute coronary syndrome, comprising the detecting the level of... Hoffmann la Roche Inc

11/02/17 / #20170314055

Enzymatic one-pot reaction for double polypeptide conjugation in a single step

Herein is reported a method for producing an enzymatic conjugation product of three polypeptides comprising the simultaneous incubation of i) a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 20, wherein X can be any amino acid residue), a second polypeptide comprising the amino acid sequence LPXTA... Hoffmann la Roche Inc

10/26/17 / #20170305964

Immunoglobulin aggregate removal

For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a... Hoffmann la Roche Inc

10/26/17 / #20170306040

Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate

The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD22 antibody-drug conjugate.... Hoffmann la Roche Inc

10/19/17 / #20170298067

Novel tetrahydropyridopyimidines and tetrahydropridopyridopyridines for the treatment and prophylaxis of hepatitis b virus infection

wherein R1, R2, R3, Q, U,W, Z, X and Y are as described herein, compositions including the compounds and methods of using the compounds. These compounds are HbsAg inhibitors and are useful as medicaments for the treatment or prophylaxis of HBV infection.... Hoffmann la Roche Inc

10/12/17 / #20170291936

Antibody light chains

The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid... Hoffmann la Roche Inc

10/12/17 / #20170292166

Novel methods for enzyme mediated polypeptide conjugation

Herein is reported a method for producing an enzymatic conjugation product of two polypeptides comprising incubating of a first polypeptide comprising the amino acid sequence LPXTG (SEQ ID NO: 20, wherein X can be any amino acid residue), a second polypeptide has an oligo-alanine Am (m=2 (SEQ ID NO: 26),... Hoffmann la Roche Inc

10/12/17 / #20170294017

Vessel analysis in multiplexed images

Systems and methods for analyzing vessels in multiplexed images include detecting large vessels using a spoke feature detection method, detecting long and narrow vessels using a line feature detection method, detecting smaller vessels using rolling-ball filtering and binary image operations to generate a mask, and evaluating any contour polygons resulting... Hoffmann la Roche Inc

10/05/17 / #20170281566

Combinations of lsd1 inhibitors for the treatment of hematological malignancies

pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.... Hoffmann la Roche Inc

10/05/17 / #20170281567

Combinations of lsd1 inhibitors for use in the treatment of solid tumors

The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).... Hoffmann la Roche Inc

10/05/17 / #20170281602

Solid forms of (s)-2-methoxy-3--propionic acid and of salts thereof

The present invention relates to solid forms of (S)-2-methoxy-3-{442-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxyl-benzo[b]thiophen-7-yl}-propionic acid, and of salts of (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid.... Hoffmann la Roche Inc

10/05/17 / #20170281609

Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and making the same

The disclosure relates to granulate formulations of pirfenidone and methods of making such formulations.... Hoffmann la Roche Inc

10/05/17 / #20170283889

Biomarkers for hbv treatment response

The present invention relates to methods that are useful for predicting the response of hepatitis B virus (HBV) infected patients to pharmacological treatment.... Hoffmann la Roche Inc

09/28/17 / #20170275253

Benzazepine sulfonamide compounds

wherein R4 or R5 is —SO2—NR7R8 and R1 to R8 and Y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune... Hoffmann la Roche Inc

09/28/17 / #20170275286

Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.... Hoffmann la Roche Inc

09/28/17 / #20170275368

Antibodies against human csf-1r and uses thereof

The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.... Hoffmann la Roche Inc

09/21/17 / #20170266175

Novel piperidine derivatives

wherein A1, A2 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.... Hoffmann la Roche Inc

09/21/17 / #20170266286

Novel pharmaceutical dosage forms comprising valganciclovir hydrochloride

The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water.... Hoffmann la Roche Inc

09/21/17 / #20170267383

Preparing a double chamber container

A method of preparing a double chamber container (1) comprises the steps of: filling a substance in the interior of the double chamber container (1), freeze-drying the substance inside the double chamber container(1), inserting a middle plunger (81) in the interior of the double chamber container (1) such that a... Hoffmann la Roche Inc

09/21/17 / #20170267736

Igf-i poly (ethylene glycol) conjugates

Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5′ to 3′ direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO:... Hoffmann la Roche Inc

09/21/17 / #20170268945

Measuring vial seal forces

The invention deals with a measuring apparatus (1) comprising a body (11) with an interior (114) and an opening for accessing the interior (114) from outside the body (11), a rigid plunger (12) having an edge (1212) being identically shaped as an edge of a opening of a target vial,... Hoffmann la Roche Inc

09/21/17 / #20170268976

In vitro analysing the behaviour of substances in simulated physiological environment

The invention refers to an in vitro method and apparatus for analysing the behaviour of substances in simulated physiological environment. The method comprises the steps of providing a first fluid, a gel matrix and a second fluid, separating the first fluid and the gel matrix by at least one first... Hoffmann la Roche Inc

09/14/17 / #20170259948

Closing a chamber of a container for a pharmaceutical product

A device (1) for closing a chamber of a container having an opening for accessing the chamber comprises a plunger, a plunger seat (11), a container carrier (13) and a spacer (12). The plunger seat (11) releasably holds the plunger in a predefined alignment. The container carrier (13) is arranged... Hoffmann la Roche Inc

09/07/17 / #20170253661

Galactoengineered immunoglobulin 1 antibodies

The present invention relates to galactoengineered recombinant antibodies of IgG1 isotype, methods for the production of said antibodies and uses thereof.... Hoffmann la Roche Inc

09/07/17 / #20170253670

Common light chains and methods of use

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention... Hoffmann la Roche Inc

Patent Packs
09/07/17 / #20170253672

Removal of monomeric targets

The present invention relates to a novel method for the removal of monomeric targets from bodily fluids, and to pharmaceutical compositions for use in such methods.... Hoffmann la Roche Inc

08/31/17 / #20170246153

Spiro-thiazolones

wherein X1, X2, X3, X4, R2, R3, R4, R5, R6 and R7 are as defined herein, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments for treatment of inappropriate secretion of vasopressin, anxiety, depressive disorders,... Hoffmann la Roche Inc

08/31/17 / #20170247440

Anti-pdgf-b antibodies and methods of use

Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.... Hoffmann la Roche Inc

08/31/17 / #20170247441

Anti-ang2 antibodies and methods of use

Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32.... Hoffmann la Roche Inc

08/31/17 / #20170247447

Anti-il-1beta antibodies and methods of use

Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a... Hoffmann la Roche Inc

08/31/17 / #20170247454

Anti-pd1 antibodies and methods of use

The present invention relates to anti-PD1 antibodies and methods of using the same.... Hoffmann la Roche Inc

08/31/17 / #20170247459

Combination therapy of antibodies against human csf-1r and uses thereof

The present invention relates to the combination therapy of antibodies binding to human CSF-1R, characterized in binding to the (dimerization) domains D4 to D5 (SEQ ID No: 85) of the extracellular domain of human CSF-1R in combination with a chemotherapeutic agent, radiation, and/or cancer immunotherapy.... Hoffmann la Roche Inc

08/31/17 / #20170247467

Bispecific antibodies with tetravalency for a costimulatory tnf receptor

The invention relates to novel bispecific antigen binding molecules, comprising (a) four moieties capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and a second... Hoffmann la Roche Inc

08/24/17 / #20170239353

Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits... Hoffmann la Roche Inc

08/24/17 / #20170240600

Tagged hepadnavirus e antigen and its use in screening antiviral substances

The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus... Hoffmann la Roche Inc

08/24/17 / #20170240626

Bispecific, bivalent anti-vegf/anti-ang-2 antibodies

The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.... Hoffmann la Roche Inc

08/24/17 / #20170240629

Bispecific antibodies and methods of use in ophthalmology

Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.... Hoffmann la Roche Inc

08/24/17 / #20170241983

Screening method

The invention discloses a screening method for the identification of new compounds for use in the treatment of cancer.... Hoffmann la Roche Inc

08/17/17 / #20170233437

Peptide macrocycles against acinetobacter baumannii

wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections... Hoffmann la Roche Inc

08/17/17 / #20170233475

Antibodies binding to human and cynomolgus cd3 epsilon

One aspect as reported herein is using a method comprising the step of immunizing an experimental animal, three times with primary cynomolgus PBLs, whereby the PBLs are optionally enriched for T cells without using primary human PBLs as immunogen and without using a denaturing agent for producing a human cynomolgus... Hoffmann la Roche Inc

Patent Packs
08/17/17 / #20170233490

Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2

The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.... Hoffmann la Roche Inc

08/17/17 / #20170233812

Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator... Hoffmann la Roche Inc

08/10/17 / #20170226079

Dihydroquinoline pyrazolyl compounds

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R15, R16, R17 and n are as described herein, compositions including the compounds and methods of using the compounds.... Hoffmann la Roche Inc

08/10/17 / #20170226085

Dihydroquinoline pyrazolyl compounds

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, m and n are as described herein, compositions including the compounds and methods of using the compounds.... Hoffmann la Roche Inc

08/10/17 / #20170226091

2,2,2-trifluoroethyl-thiadiazines

The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.... Hoffmann la Roche Inc

08/10/17 / #20170226097

Pyridinyloxy- and phenyloxy-pyrazolyl compounds

wherein R1, R2 and n are as described herein, compositions including the compounds and methods of using the compounds.... Hoffmann la Roche Inc

08/10/17 / #20170226116

New dihydroquinoline pyrazolyl compounds

wherein R1, R2, R3, R4, R5, R6, R7, R8, R10, R11, R12, R13, R14, R15, R16, R17 and m are as described herein, compositions including the compounds and methods of using the compounds.... Hoffmann la Roche Inc

08/10/17 / #20170226555

Thiol-based deep eutectic solvent

A deep eutectic solvent consisting of (2-hydroxyethyl) trimethyl ammonium chloride and dithiothreitol in a molar ratio of from 1:2 to 1:3 and from 0% to 10% co-solvent, and methods of enzymatic production of polypeptides using the deep eutectic solvent.... Hoffmann la Roche Inc

08/10/17 / #20170227544

Methods for personalizing patient cancer therapy with an mdm2 antagonist

The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with an MDM2 antagonist of formulae I, II and III as disclosed herein, said method comprising a multivariate analysis comprising detecting relative amounts of certain MDM2 protein expressing cells and, optionally additional co-variates selected... Hoffmann la Roche Inc

08/10/17 / #20170227547

In vitro prediction of in vivo half-life

Herein is reported a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex influencing the in vivo half-life comprising the steps of a) determining the retention time of the antibody on an FcRn affinity chromatography column with a positive linear pH gradient elution in the presence of... Hoffmann la Roche Inc

08/03/17 / #20170216214

Formulations

The present invention relates to a hygroscopic matrix based composition, a process for the preparation thereof and its use in the treatment of diseases.... Hoffmann la Roche Inc

08/03/17 / #20170217926

Ethynyl derivatives

The present invention relates to ethynyl derivatives as metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).... Hoffmann la Roche Inc

08/03/17 / #20170217990

Novel compounds for the treatment of infectious diseases

wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.... Hoffmann la Roche Inc

07/27/17 / #20170209573

Treatment method

The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent. The invention further relates to methods of treating a disease, particularly a B-cell proliferative disorder, and methods for reduction of... Hoffmann la Roche Inc

07/27/17 / #20170210785

Rapid cloning and expression of cognate antibody variable region gene segments

In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate... Hoffmann la Roche Inc

07/27/17 / #20170211876

Method for selecting antibodies with modified fcrn interaction

Herein is reported a method for selecting a full length antibody comprising the steps of a) generating from a parent full length antibody a plurality of full length antibodies by randomizing one or more amino acid residues selected from the amino acid residues at positions 1-23 in the heavy chain... Hoffmann la Roche Inc

07/27/17 / #20170211959

Dosing a fluid at a volume of less than one milliliter

A peristaltic dosing device for providing dosages of a fluid at a volume of less than one milliliter comprises: a flexible tube, a counter pressure element, a plurality of actors and a drive. The flexible tube is essentially straightly arranged along the counter pressure element thereby forming a longitudinal axis.... Hoffmann la Roche Inc

07/27/17 / #20170212068

Method for determining whether reconstitution of a solution in a container is completed

determining that reconstitution of the solution is completed when the change of the measured impedance (Z) is below the defined threshold.... Hoffmann la Roche Inc

07/27/17 / #20170212107

Velocity factor

The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor... Hoffmann la Roche Inc

07/20/17 / #20170204103

Novel triazolo[4,5-d]pyrimidines

wherein R1 to R4 and n are defined as in the description and in the claims. The compound of formula (I) can be for treating.... Hoffmann la Roche Inc

07/20/17 / #20170204107

Spirodiamine derivatives as aldosterone synthase inhibitors

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R5, A1, A2, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.... Hoffmann la Roche Inc

07/20/17 / #20170204182

Vh-vl-interdomain angle based antibody humanization

Herein is reported a method for selecting one or more variant antibody Fv fragments derived from a parent antibody Fv fragment comprising the steps of i) generating a multitude of variant antibody Fv fragments by grafting/transferring one or more specificity determining residues from the parent antibody Fv fragment on an... Hoffmann la Roche Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Hoffmann la Roche Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Hoffmann la Roche Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###